FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292313263> ?p ?o ?g. }

• W4292313263 abstract "Objective Considering the striking evidence revealed by immunotherapy in advanced or metastatic bladder cancer, investigators have explored neoadjuvant immunotherapy and chemoimmunotherapy in muscle-invasive bladder cancer (MIBC). Currently, there have been a large number of studies reporting varied efficacy and safety of these approaches. Herein, we pooled the available evidence in terms of oncological outcomes (pathological complete response [pCR] and pathological partial response [pPR]) and safety outcomes (immune-related adverse events [irAEs], treatment-related adverse events [TRAEs]), through a systematic review and meta-analysis. Method We searched PubMed, Embase, Cochrane Library, and American Society of Clinical Oncology meeting abstracts to identify relevant studies up to June 2022. Studies were included if they evaluated the neoadjuvant immunotherapy or chemoimmunotherapy in MIBC and reported at least the pCR. Results A total of 22 records involving 843 patients were included. For pCR of immunotherapy, the pooled rate of immune checkpoint inhibitor (ICI) monotherapy and dual-ICIs therapy was 24% (95% confidence interval [CI]: 15.3% - 32.8%) and 32.1% (95%CI: 20.6% - 43.7%), respectively. For pCR of chemoimmunotherapy, the overall pooled rate was 42.6% (95% CI: 34.9% - 50.2%). Subgroup of gemcitabine/cisplatin (GC) plus ICI had a pCR rate of 41.7% (95%CI: 35.8% - 47.5%). In terms of safety, the pooled rate of Grade≥3 irAEs was 11.7% (95% CI: 6.5%-16.9%). In subgroup analysis, the Grade≥3 irAEs rate of ICI monotherapy, dual-ICIs therapy, and GC plus ICI therapy was 7.4% (95% CI: 4.3%-10.5%), 30.3% (95% CI: 15.3%-45.3%), and 14.5% (95% CI: 3.5% - 25.4%), respectively. Besides, the pooled Grade≥3 TRAEs rate for chemoimmunotherapy was 32.4% (95% CI: 13.1% - 51.6%). Conclusion Neoadjuvant immunotherapy and chemoimmunotherapy were effective and safe in the treatment of MIBC. Compared to ICI monotherapy, dual-ICIs therapy or chemoimmunotherapy can improve the response rate, while increasing the morbidity of Grade≥ 3 irAEs or Grade≥ 3 TRAEs. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD4202233771." @default.
• W4292313263 created "2022-08-19" @default.
• W4292313263 creator A5045995219 @default.
• W4292313263 creator A5053869162 @default.
• W4292313263 creator A5056860634 @default.
• W4292313263 creator A5059770499 @default.
• W4292313263 creator A5066565099 @default.
• W4292313263 creator A5074707571 @default.
• W4292313263 date "2022-08-17" @default.
• W4292313263 modified "2023-09-30" @default.
• W4292313263 title "Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer" @default.
• W4292313263 cites W1607745684 @default.
• W4292313263 cites W1964037817 @default.
• W4292313263 cites W1971158225 @default.
• W4292313263 cites W1985213644 @default.
• W4292313263 cites W1987446429 @default.
• W4292313263 cites W2017044005 @default.
• W4292313263 cites W2052874737 @default.
• W4292313263 cites W2064827653 @default.
• W4292313263 cites W2112601576 @default.
• W4292313263 cites W2128758225 @default.
• W4292313263 cites W2152762320 @default.
• W4292313263 cites W2550294854 @default.
• W4292313263 cites W2559804019 @default.
• W4292313263 cites W2560282005 @default.
• W4292313263 cites W2563390944 @default.
• W4292313263 cites W2572174216 @default.
• W4292313263 cites W2582671354 @default.
• W4292313263 cites W2587486634 @default.
• W4292313263 cites W2597872842 @default.
• W4292313263 cites W2769488285 @default.
• W4292313263 cites W2806413184 @default.
• W4292313263 cites W2890892325 @default.
• W4292313263 cites W2912993305 @default.
• W4292313263 cites W2921480061 @default.
• W4292313263 cites W2941126703 @default.
• W4292313263 cites W2975424845 @default.
• W4292313263 cites W2976744492 @default.
• W4292313263 cites W2988581606 @default.
• W4292313263 cites W2990281693 @default.
• W4292313263 cites W3006134372 @default.
• W4292313263 cites W3008737262 @default.
• W4292313263 cites W3008870350 @default.
• W4292313263 cites W3024551702 @default.
• W4292313263 cites W3030130251 @default.
• W4292313263 cites W3032884379 @default.
• W4292313263 cites W3033340144 @default.
• W4292313263 cites W3092138236 @default.
• W4292313263 cites W3092302767 @default.
• W4292313263 cites W3102493364 @default.
• W4292313263 cites W3118768174 @default.
• W4292313263 cites W3135321607 @default.
• W4292313263 cites W3144543375 @default.
• W4292313263 cites W3146142859 @default.
• W4292313263 cites W3159113597 @default.
• W4292313263 cites W3167908569 @default.
• W4292313263 cites W3186722350 @default.
• W4292313263 cites W3202515919 @default.
• W4292313263 cites W3202811014 @default.
• W4292313263 cites W3211495808 @default.
• W4292313263 cites W3217070743 @default.
• W4292313263 cites W4210363402 @default.
• W4292313263 cites W4212984292 @default.
• W4292313263 cites W4213038487 @default.
• W4292313263 cites W4213148713 @default.
• W4292313263 cites W4213285022 @default.
• W4292313263 cites W4214569549 @default.
• W4292313263 cites W4244288707 @default.
• W4292313263 cites W4251612516 @default.
• W4292313263 cites W4286295282 @default.
• W4292313263 cites W4286297436 @default.
• W4292313263 doi "https://doi.org/10.3389/fimmu.2022.986359" @default.
• W4292313263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36059550" @default.
• W4292313263 hasPublicationYear "2022" @default.
• W4292313263 type Work @default.
• W4292313263 citedByCount "7" @default.
• W4292313263 countsByYear W42923132632023 @default.
• W4292313263 crossrefType "journal-article" @default.
• W4292313263 hasAuthorship W4292313263A5045995219 @default.
• W4292313263 hasAuthorship W4292313263A5053869162 @default.
• W4292313263 hasAuthorship W4292313263A5056860634 @default.
• W4292313263 hasAuthorship W4292313263A5059770499 @default.
• W4292313263 hasAuthorship W4292313263A5066565099 @default.
• W4292313263 hasAuthorship W4292313263A5074707571 @default.
• W4292313263 hasBestOaLocation W42923132631 @default.
• W4292313263 hasConcept C121608353 @default.
• W4292313263 hasConcept C126322002 @default.
• W4292313263 hasConcept C143998085 @default.
• W4292313263 hasConcept C187960798 @default.
• W4292313263 hasConcept C197934379 @default.
• W4292313263 hasConcept C2775949291 @default.
• W4292313263 hasConcept C2777701055 @default.
• W4292313263 hasConcept C2778292576 @default.
• W4292313263 hasConcept C2780057760 @default.
• W4292313263 hasConcept C2780258809 @default.
• W4292313263 hasConcept C2780352672 @default.
• W4292313263 hasConcept C2780790343 @default.
• W4292313263 hasConcept C530470458 @default.
• W4292313263 hasConcept C71924100 @default.
• W4292313263 hasConcept C95190672 @default.

• next